Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The value of low-dose diethylstilbestrol (DES) in the management of men with advanced and castration-resistant prostate cancer (CRPC) comes up as a regular topic for review and discussion. Before development of the LHRH agonists, DES was the most commonly used — and much studied — drug for the treatment of advanced (metastatic) prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant prostate cancer, CRPC, DES, diethylstilbestrol | Leave a Comment »
A story on the Bloomberg.com web site gives information about a patient with castration-resistant prostate cancer (CRPC) who has had a zero-level PSA for 40 months since starting on a clinical trial of abiraterone actetate in early 2008.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, CRPC, orteronel, survival, TAK-700 | 3 Comments »
An article from Thursday’s “The Pink Sheet”, posted on the OncologySTAT web site today, is already asking questions about the potential future use of abiraterone acetate in patients with non-metastatic, castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, cabazitaxel, castration-resistant prostate cancer, CRPC | 12 Comments »
Patients and others with a strong interest in understanding the ways in which new drugs like abiraterone acetate and MDV3100 are likely to change the way we treat advanced forms of prostate cancer might be interested in a webcast based on a satellite symposium held at the recent Genitourinary Cancers Symposium in Orlando.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, CRPC, MDV3100 | Leave a Comment »
According to a media release issued by AstraZeneca earlier today, the company has stopped a second clinical trial of their endothelin receptor antagonist zibotentan because “zibotentan monotherapy was unlikely to meet its primary efficacy endpoints … and therefore unlikely to benefit patients with non-metastatic CRPC.”
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, endothelin, zibotenan | Leave a Comment »
KW-2170 is a drug that had been undergoing early clinical trials in Australia for the treatment of men with castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, KW-2170 | Leave a Comment »
Data from a small Phase II trial of cilengitide suggest that it has minimal clinical effect in the treatment of men with non-metastatic, castration-resistant prostate cancer (CRPC). They also suggest that levels of circulating T-cells (CTCs) are of limited utility in monitoring the progression of this patient group.
Filed under: Drugs in development | Tagged: castration-resistant, cilengitide, circulating T-cell, CRPC, CTC | Leave a Comment »
Ketoconazole has long been used as a “third-line” agent in men with castration-resistant prostate cancer (CRPC) who have progressive disease after standard forms of hormonal therapy. For some patients, ketoconazole can be clinically effective and cost-effective compared to other clinical options.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: acid, acid-suppressive, castration-resistant, CRPC, ketoconazole, suppression | 5 Comments »
An announcement yesterday has made it clear that sunitinib malate (Sutent) is unlikely to ever show significant clinical activity in the management of patients with advanced, castration-resistant prostate cancer (CRPC) after initial chemotherapy.
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, sunitinib | Leave a Comment »
On his Advanced Prostate Cancer blog site, Joel Nowak has just published a series of five brief articles on the opportunities offered by some older agents that are available for use as second-line therapies in the management of patients who have a rising PSA after treatment with standard forms of androgen deprivation therapy (ADT).
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: advanced, castration-resistant, CRPC, estradiol, GM-CSF, ketoconazole, octreotide | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site